Physician profile
John N Margolis
NPI 1346231669
$492.66
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $27.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $127.21 | 2019 | |
| Pfizer INC. | $40.12 | 2019 | |
| Amarin Pharma, INC. | $36.95 | 2019 | |
| Astellas Pharma US INC | $35.21 | 2019 | |
| Lilly USA, LLC | $34.70 | 2019 | |
| Amgen INC. | $33.24 | 2019 | |
| Merck Sharp & Dohme LLC | $30.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.15 | 2019 | |
| Allergan, INC. | $27.26 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.57 | 2019 | |
| Abbvie INC. | $21.11 | 2019 | |
| Horizon Therapeutics Plc | $16.10 | 2019 | |
| Sanofi Pasteur INC. | $15.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.